Niu, Dongfeng
Li, Lei
Yu, Yang
Zang, Wanchun
Li, Zhongwu
Zhou, Lixin
Jia, Ling
Rao, Guanhua
Gao, Lianju
Cheng, Gang
Ji, Ke
Lin, Dongmei
Funding for this research was provided by:
Natural Science Foundation of China (81472743)
Article History
Received: 25 May 2020
Accepted: 10 June 2020
First Online: 3 July 2020
Ethics Approval and Consent to Participate
: This study was approved by the ethics committee of Peking University Cancer Hospital (2014TW04), and written informed consent was obtained from all patients.
: Lei Li, Wanchun Zang, Lianju Gao, Guanhua Rao, Yun Gao, Gang Cheng and Yang Yu were employee of Novogene Bioinformatics Technology Co., Ltd., Beijing, China. No potential conflicts of interest were disclosed by the other authors. SJK has received consulting/advisory fees from Lilly Oncology, Astellas, Boston Biomedical and Foundation Medicine, Inc. SJK has stock/equity in TP Therapeutics and receives institutional research funding from Merck, Leap therapeutics, and Astellas Pharmaceuticals.